Patient perspective on psoriasis: Psychosocial burden of psoriasis and its management in Malaysia
Open Access
- 18 July 2024
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 19 (7) , e0305870
Abstract
Background: Psoriasis is a chronic erythematous inflammatory skin disorder. The major challenge with psoriasis is delayed diagnosis, resulting in delayed treatment initiation and reduced quality of life (QoL). Objective: This patient perspective study aimed to explore the emotional and psychosocial burdens faced by patients with psoriasis in Malaysia and their attitudes toward current psoriasis treatment. Methods: Adult patients with mild or moderate-to-severe plaque psoriasis, preferably with concomitant psoriatic arthritis, participated in a patient advisory board meeting along with a senior consultant dermatologist. Patients had to describe their initial symptoms, time of diagnosis, misdiagnosis, treatment initiation delays, treatment course, flare-ups, psychosocial impact, and QoL associated with psoriasis. Results: The 11 participating patients had a mean age of 46 years with mean age of psoriasis diagnosis and an average year of suffering with psoriasis being 21.9 years and 24.5 years, respectively. The most common initial symptom of psoriasis was itching (62.5%), particularly of the scalp followed by itchiness and red patches on skin. Most patients (90%) reported initial misdiagnosis with other skin diseases by their primary care physicians (PCPs), which led to delayed treatment initiation. Most patients reported an emotional impact of psoriasis, including low self-esteem (18%), lack of confidence (27%), shock (18%), sadness (9%), and outrage (9%). Social discrimination/stigmatization in public places and at work (45%), and even from relatives (18%) was another reported challenge. However, 73% of patients were highly satisfied with the current treatment. Overall, the patients agreed that the lack of public awareness of psoriasis was responsible for the social stigma. Conclusions: The evidence obtained from this qualitative study indicated that psoriasis has a significant emotional and psychological impact on the patients affecting their QoL. Lack of awareness of the disease among PCPs, patients, and the public is a major challenge leading to poor treatment outcomes.Keywords
Funding Information
- Johnson & Johnson
This publication has 33 references indexed in Scilit:
- Microneedles as a momentous platform for psoriasis therapy and diagnosis: A state-of-the-art reviewInternational Journal of Pharmaceutics, 2023
- Nanocarriers for the topical treatment of psoriasis - pathophysiology, conventional treatments, nanotechnology, regulatory and toxicologyEuropean Journal of Pharmaceutics and Biopharmaceutics, 2022
- A Digital Therapeutic for Management of Psychosocial Aspects of Psoriasis: A Pre-Post Proof of Concept StudySkin Health and Disease, 2022
- Demographic and Clinical Factors Associated with Patient-Reported Remission in PsoriasisDermatology and Therapy, 2022
- Evolution of Patient Perceptions of Psoriatic Disease: Results from the Understanding Psoriatic Disease Leveraging Insights for Treatment (UPLIFT) SurveyDermatology and Therapy, 2021
- The Impact of Stigmatization of Psoriasis, Atopic Dermatitis and Mastocytosis in Different Areas of Life—A Qualitative Interview StudySkin Health and Disease, 2021
- Disease burden and treatment challenges of psoriatic arthritis in Africa and the Middle EastRheumatology International, 2019
- Prevalence of psoriatic arthritis in patients with psoriasis: A systematic review and meta-analysis of observational and clinical studiesJournal of the American Academy of Dermatology, 2019
- Patient perspectives in the management of psoriasis: Results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis SurveyJournal of the American Academy of Dermatology, 2014
- Global Epidemiology of Psoriasis: A Systematic Review of Incidence and PrevalenceJournal of Investigative Dermatology, 2013